US drug major Schering-Plough has completed its acquisition of Organon BioSciences from Netherlands-based Akzo Nobel for 11.0 billion euros ($16.3 billion; Marketletters passim). This includes human and animal health units, the vaccines operation Nobilon as well as the Diosynth manufacturing division, which will boost S-P's pipeline and R&D capacity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze